5 Key Takeaways
-
1
Understanding payer rules is essential for ensuring payment for administered retina drugs and biosimilars.
-
2
Diagnosis codes must align with FDA-approved indications and individual payer policies to avoid claim denials.
-
3
Practices should utilize Coding and Billing Guides from manufacturers to verify approved diagnoses for retina drugs.
-
4
Effective communication among staff regarding payer policies is crucial to prevent claim denials and financial issues.
-
5
Staying informed about changes in payer policies through alerts and newsletters is vital for practice sustainability.
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.







